Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of PF-07328948 in Hepatic Impairment
NCT07269301Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-07328948 (4 arms), sponsored by Pfizer. Primary endpoints: Fraction of Unbound Drug in Plasma at 168 hours, Unbound Area Under the Curve from Time Zero to Infinity at 168 hours and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
PF-07328948
Beyond the preview
Go deeper on NCT07269301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269301.